All Articles

In an interview with Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG, we learn how enhanced healthcare provider communication skills can improve patients’ quality of life and confidence to navigate the complexities of end-of-life care.

Whether they are currently undergoing breast cancer treatment, supporting a loved one, or seeking to become a community ally, the Tigerlily Foundation’s ANGEL Advocacy Program can offer people comprehensive advocacy training, educational resources, and the support of a warm community.

A precise and comprehensive understanding of survivorship and its phases is essential for improving patient care throughout their cancer journey.

Awardees Honored at the AONN+ Annual Conference Highlighting awardees honored at the 2024 AONN+ Annual Conference.

Langhorne, PA – January 16, 2025 - The Journal of Oncology Navigation & Survivorship (JONS), Amplity’s premier oncology navigation journal, and the Tigerlily Foundation (Tigerlily) have partnered to advance two innovative health equity initiatives: comprehensive breast cancer advocacy training and clinical trial education and community engagement. Both efforts aim to address the unique and often overlooked needs of Black, Brown, and underserved women facing breast cancer, with a focus on creating lasting change within these communities.

This article summarizes 2 analyses from the phase 3 GMMG-HD7 trial presented at ASH 2024, as well as the FDA’s Oncologic Drugs Advisory Committee support for the use of minimal residual disease as an accelerated approval endpoint in multiple myeloma clinical trials.

In this article, the results from 2 studies of Isa-KRd in newly diagnosed multiple myeloma (NDMM) are summarized, with the GMMG-CONCEPT trial focusing on high-risk NDMM and the IFM 2020-02 MIDAS study focusing on transplant-eligible NDMM.

This article summarizes a post-hoc analysis of data from the MASTER study and the GRIFFIN study of patients with newly diagnosed multiple myeloma with high-risk cytogenetic abnormalities.

This article summarizes results from an ad hoc survey conducted to evaluate nurses’ experiences with subcutaneous isatuximab administration via an on-body delivery system.

As we reflect on the many steps forward navigation has taken in 2024, it’s crucial that we also look ahead at the opportunities for advancement in 2025, collectively and individually.